2025-12-19 - Analysis Report
Okay, here's a comprehensive analysis of Intuitive Surgical Inc. (ISRG) based on the provided data.

**0) Overview & Disclaimer**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets the da Vinci surgical system and related instruments and accessories.

**1) Return Rate Comparison**

*   **ISRG Cumulative Return:** 107.68%
*   **VOO (S&P 500) Cumulative Return:** 99.09%
*   **Divergence:**
    *   **Current:** 5.2
    *   **Relative Divergence:** 31.5
*   **Analysis:** ISRG has outperformed the S&P 500 (VOO) over the total data period. The current divergence of 5.2 indicates that ISRG's recent performance is not significantly above or below the VOO return. The relative divergence of 31.5 suggests the current divergence is in the lower end of its historical fluctuation range relative to VOO.

**Alpha, Beta Analysis**

| Year       | CAGR   | MDD    | Alpha  | Beta | Cap(B) |
|------------|--------|--------|--------|------|--------|
| 2015-2017  | 68.0%  | 77.6%  | 40.0%  | -0.1 | 43.6   |
| 2016-2018  | 64.0%  | 72.2%  | 49.0%  | -0.0 | 57.2   |
| 2017-2019  | 54.0%  | 72.2%  | 31.0%  | 0.2  | 70.6   |
| 2018-2020  | -6.0%  | 80.4%  | -29.0% | 0.3  | 97.8   |
| 2019-2021  | 29.0%  | 80.4%  | -18.0% | 0.6  | 128.8  |
| 2020-2022  | -23.0% | 80.4%  | -22.0% | 1.2  | 95.1   |
| 2021-2023  | -17.0% | 77.5%  | -18.0% | 1.7  | 120.9  |
| 2022-2024  | 36.0%  | 77.5%  | 15.0%  | 1.7  | 187.1  |
| 2023-2025  | 70.0%  | 72.7%  | 6.0%   | 0.8  | 201.4  |

*   **CAGR:** The Compound Annual Growth Rate shows strong growth in most periods, with exceptions (2018-2020, 2020-2022, 2021-2023) indicating periods of underperformance. The most recent period (2023-2025) shows a significant resurgence in growth.
*   **MDD:** The Maximum Drawdown figures are high, suggesting substantial volatility and risk in the stock's price.
*   **Alpha:** Alpha measures the excess return of the investment relative to the market. Negative Alpha values for the 2018-2023 periods indicate underperformance compared to the market on a risk-adjusted basis.  More recent periods have positive, but relatively modest, alpha.
*   **Beta:** Beta measures the stock's volatility relative to the market. The Beta values increased over time, suggesting that ISRG became more correlated with and sensitive to market movements.  The recent period has seen the beta decrease from 1.7 to 0.8.
*   **Cap(B):** Market capitalization has generally grown, showcasing company expansion and investor confidence, though it dipped in 2020-2022.

**2) Recent Stock Price Fluctuations**

*   **Current Close:** 561.89
*   **Previous Close:** 556.86
*   **Change:** 0.9
*   **5-day SMA:** 555.03
*   **20-day SMA:** 563.07
*   **60-day SMA:** 520.55
*   **Analysis:** The stock price is currently slightly below its 20-day SMA, but above its 5-day SMA, and significantly above the 60-day SMA.  This suggests a recent upward trend, though slightly weakening compared to the very short-term average. The "change" figure (0.9) indicates a recent moderate upward movement in price.

**3) Indicators**

*   **MRI (Market Risk Indicator):** 0.7 (Medium Investment Recommendation)
*   **RSI:** 43.00
*   **PPO:** -0.57
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Relative Divergence Change (20 days):** 0.0 (단기하락 - short-term decline)
*   **Expected Return:** 28.5%
*   **Analysis:**
    *   The MRI of 0.7 suggests a medium level of risk, indicating a moderately favorable investment environment.
    *   The RSI of 43.00 is below 50, suggesting the stock is not overbought but not oversold either.  There's room for potential upward movement.
    *   The PPO of -0.57 indicates that the short-term moving average is slightly below the long-term moving average, potentially suggesting a slight downtrend or a pause in the uptrend.
    *   The Hybrid Signal recommends a full investment, indicating a bullish outlook.
    *   The recent decline in relative divergence indicates short-term underperformance against the S&P 500.
    *   The expected return of 28.5% is quite high and indicates strong confidence in the stock's long-term potential.

**4) Recent News & Significant Events**

*   **Positive Analyst Outlook:** Multiple articles indicate positive sentiment from analysts, with Truist Financial raising the price target to $650 (MarketBeat, GuruFocus).
*   **Key Catalysts for 2026:**  One article mentions key catalysts for 2026 (ts2.tech), suggesting continued growth potential.
*   **Upward Price Movement:**  One article highlights a 2% increase in the stock price (Quiver Quantitative).
*   **Competition:**  One article compares ISRG to Medtronic (MDT) in the robotics space (Yahoo Finance).
*   **Key Support Level:**  One article suggests the stock hit a key support level, potentially a buying opportunity (Trefis).
*   **Analysis:** The news sentiment is largely positive, driven by analyst upgrades and potential catalysts. The competition with Medtronic is a factor to monitor. The identified support level is noteworthy for potential investors.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 2.06)
*   **Target Price:** Average: $598.57, High: $700.00, Low: $378.00
*   **Recent Rating Changes:** No changes provided in the data.
*   **Analysis:** The analyst consensus is strongly bullish with a "Buy" rating. The average target price suggests potential upside from the current price.

**5) Recent Earnings Analysis**

| Date       | EPS  | Revenue     |
|------------|------|-------------|
| 2025-10-22 | 1.98 | 2.51 B$    |
| 2025-07-23 | 1.84 | 2.44 B$    |
| 2025-04-23 | 1.95 | 2.25 B$    |
| 2024-10-18 | 1.59 | 2.04 B$    |
| 2025-10-22 | 1.59 | 2.04 B$    |
| 2025-10-22 | 1.59 | 2.04 B$    |
| 2025-10-22 | 1.59 | 2.04 B$    |
| 2025-10-22 | 1.59 | 2.04 B$    |
*Note: There appear to be duplicate entries in the data.*

*   **Analysis:** There's a clear upward trend in both EPS and Revenue. The EPS has increased from $1.59 to $1.98, and revenue has grown from $2.04B to $2.51B.  This indicates strong financial performance and growth for the company.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue   | Profit Margin |
|--------------|-----------|---------------|
| 2025-09-30   | $2.51B    | 66.36%        |
| 2025-06-30   | $2.44B    | 66.31%        |
| 2025-03-31   | $2.25B    | 64.69%        |
| 2024-12-31   | $2.41B    | 68.04%        |
| 2024-09-30   | $2.04B    | 67.41%        |

**Capital and Profitability:**

| Quarter      | Equity    | ROE     |
|--------------|-----------|---------|
| 2025-09-30   | $16.93B   | 4.16%   |
| 2025-06-30   | $17.85B   | 3.69%   |
| 2025-03-31   | $17.11B   | 4.08%   |
| 2024-12-31   | $16.43B   | 4.17%   |
| 2024-09-30   | $15.58B   | 3.63%   |

*   **Analysis:**
    *   **Revenue and Profitability:** Revenue has generally increased over the past several quarters, indicating growth in sales. The profit margin remains very high, showcasing the company's efficient operations and strong pricing power.
    *   **Capital and Profitability:** Equity has generally increased over the period. ROE (Return on Equity) fluctuates, but it is generally at a high level which indicates effective use of shareholder equity to generate profits.

**7) Comprehensive Analysis**

Intuitive Surgical (ISRG) demonstrates a compelling investment profile based on the provided data:

*   **Strong Financial Performance:** Consistent revenue and earnings growth, coupled with high profit margins and ROE, reflect a financially healthy and growing company.
*   **Positive Outlook:** Analyst ratings, target prices, and news sentiment are largely positive, indicating confidence in the company's future prospects.
*   **Market Leadership:** ISRG maintains a leading position in the robotic surgery market, although competition exists.
*   **Technical Indicators:** The RSI is neutral, the PPO is slightly negative (suggesting a potential pause), and the hybrid signal recommends investment. The short-term relative divergence suggests a recent weakening compared to the overall market.
*   **Risks:** The high MDD (Maximum Drawdown) values highlights volatility. The increasing beta over past years indicates a heightened sensitivity to market fluctuations.
*   **Overall:** ISRG appears to be a promising investment, particularly for the long term, based on its strong financial performance, positive outlook, and leadership in a growing market. However, potential investors should be aware of the stock's volatility and sensitivity to broader market trends.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.